Bonraybio Co., Ltd.
Bonraybio Co., Ltd., a development stage company, manufactures medical instruments and solutions for the male infertility market. The company provides LensHooke X12 PRO semen analysis systems; and LensHooke X1 PRO semen quality analyzers. It also offers consumables, such as CS3 semen test slides; CA0/CA1 sperm separation solutions; and CS1 semen test cassettes. In addition, the company provides X… Read more
Bonraybio Co., Ltd. (6955) - Total Liabilities
Latest total liabilities as of September 2025: NT$50.28 Million TWD
Based on the latest financial reports, Bonraybio Co., Ltd. (6955) has total liabilities worth NT$50.28 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bonraybio Co., Ltd. - Total Liabilities Trend (2021–2024)
This chart illustrates how Bonraybio Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bonraybio Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of Bonraybio Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The BORN Korea
KO:475560
|
Korea | ₩79.81 Billion |
|
SPARQ Corp.
OTCQB:SPRQF
|
USA | $801.55K |
|
Dicot AB
ST:DICOT
|
Sweden | Skr12.10 Million |
|
SKY Metals Ltd
AU:SKY
|
Australia | AU$1.48 Million |
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
Thailand | ฿1.58 Billion |
|
Surrozen Inc
NASDAQ:SRZN
|
USA | $117.56 Million |
|
Me2on Co. Ltd
KQ:201490
|
Korea | ₩52.04 Billion |
|
KPX Chemical
KO:025000
|
Korea | ₩195.44 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down Bonraybio Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bonraybio Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bonraybio Co., Ltd. (2021–2024)
The table below shows the annual total liabilities of Bonraybio Co., Ltd. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$51.45 Million | +32.57% |
| 2023-12-31 | NT$38.81 Million | +42.51% |
| 2022-12-31 | NT$27.23 Million | +6.30% |
| 2021-12-31 | NT$25.61 Million | -- |